Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07477600
PHASE1/PHASE2

cfMSC Stem Cell Therapy Targeting COPD

Sponsor: Shenzhen Geno-Immune Medical Institute

View on ClinicalTrials.gov

Summary

The primary objectives are to evaluate the safety and efficacy of infusion of fully characterized clonally derived fetal mesenchymal stem cells (cfMSCs) for the control of severe symptoms associated with moderate to severe chronic obstructive pulmonary disease.

Official title: Clonal Fetal Mesenchymal Stem Cell Therapy for the Treatment of Chronic Obstructive Pulmonary Disease

Key Details

Gender

All

Age Range

40 Years - 80 Years

Study Type

INTERVENTIONAL

Enrollment

30

Start Date

2026-03-10

Completion Date

2030-04-30

Last Updated

2026-03-25

Healthy Volunteers

No

Interventions

BIOLOGICAL

clonal fetal MSCs

cfMSCs to treat Chronic Obstructive Pulmonary Disease

Locations (1)

Shenzhen Geno-immune Medical Institute

Shenzhen, Guangdong, China